Lee Moffitt Cancer Center & Research Institute is a nonprofit cancer treatment center located on the Tampa campus of the University of South Florida. History History of the Moffitt Cancer Centerįounded in 1986, the H. For more information, call 1-888-MOFFITT (1-88), visit, and follow the momentum on Facebook, Twitter, Instagram and YouTube. With more than 7,500 team members, Moffitt has an economic impact in the state of $2.4 billion. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. The Tampa-based facility is one of only 52 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. In 2022, the company will launch a first of its kind, comprehensive end-to-end oncology solution.įor more information and the latest updates about Employer Direct Healthcare, visit and follow us on LinkedIn. The company’s solutions democratize healthcare for its members, facilitating access to top-quality care at fair prices nationwide.Įmployer Direct Healthcare’s first product, SurgeryPlus®, is the market-leading surgical benefit, providing full-service concierge and network services to millions of covered members across hundreds of employers.
The network will be supported by two additional foundational components, digital and human led navigation and support, in partnership with Jasper Health (an intelligent digital engagement platform that provides end-to-end care guidance for people diagnosed with cancer).Ībout Employer Direct Healthcare and SurgeryPlus®Įmployer Direct Healthcare is a market-leading healthcare services business providing high-quality and cost-efficient solutions for self-funded employers and their members. EDH’s network of leading cancer centers is a foundational component of the comprehensive end-to-end oncology solution being launched in 2022. This partnership helps make our advanced therapies and clinical trials available to more cancer patients.”Įmployer Direct Healthcare is continuing to expand its network of NCI-designated cancer centers, building a solution that is inclusive of partners with the shared mission of democratizing access to best-in-class expertise based on patient need. Regarding the partnership, Patrick Skinner, Manager of Employer Relations Outreach at Moffitt stated that “Joining the EDH network of NCI-designated cancer centers is an opportunity for Moffitt to save more lives by providing the best care to those who need it most. will contribute greatly to our mission of improving outcomes regardless of where someone lives.” Making their expertise accessible to more patients throughout the U.S. They are at the forefront of cancer centers worldwide, pioneering advancements in research, diagnosis and treatment. Escobar, EDH Chief Medical Officer shared, “Having Moffitt’s cutting-edge expertise as part of our network is exciting. We are thrilled to have Moffitt’s bold innovation, expertise and multidisciplinary approach to cancer care, research and treatment as part of our network and available to our members.”ĭr. This requires us to work with partners who are the best in their field and willing to break the mold of today’s current standards. “Our network is being built on the premise that every individual deserves access to best-in-class cancer expertise” shared Dickon Waterfield, EDH Chief Strategy Officer. Moffitt is one of the first NCI-designated cancer centers to join Employer Direct Healthcare’s national network committed to ensuring patients throughout the United States have access to the best-in-class cancer expertise. participating in the National Comprehensive Cancer Network has joined it’s network of leading cancer centers.
Employer Direct Healthcare welcomes Moffitt Cancer Center, Florida’s only National Cancer Institute -Designated Comprehensive Cancer Center to the network supporting its first-of-its-kind oncology solution.
0 kommentar(er)
